How should one monitor for and manage CMV reactivation in patients receiving alemtuzumab?

Here's how I approach it:

1. Baseline Testing:

   • Perform CMV serology (IgG/IgM) and quantitative CMV DNA PCR before initiating alemtuzumab to establish baseline status.

2. Frequency:

   • Weekly PCR testing for 8–12 weeks post-infusion, focusing on the high-risk window (weeks 3–6).

   • Extend monitoring ...